問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Pediatrics

更新時間：2023-09-19

徐仲豪
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

10Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

徐仲豪

List

15Cases

2020-05-01 - 2026-12-31

Phase II

Active
AN OPEN LABEL STUDY OF RISDIPLAM IN INFANTS WITH GENETICALLY DIAGNOSED AND PRESYMPTOMATIC SPINAL MUSCULAR ATROPHY

  • Condition/Disease

    spinal muscular atrophy

  • Test Drug

    Risdiplam

Participate Sites
1Sites

Recruiting1Sites

2020-10-30 - 2039-12-04

Phase III

Active
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF 06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

  • Condition/Disease

    Duchenne Muscular Dystrophy

  • Test Drug

    PF-06939926

Participate Sites
3Sites

Recruiting3Sites

2017-09-01 - 2023-12-29

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2015-01-26 - 2025-06-02

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2020-04-01 - 2026-09-30

Phase II/III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2021-04-01 - 2027-01-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2024-07-01 - 2029-08-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting2Sites

2022-03-01 - 2024-09-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2021-11-01 - 2026-02-09

Phase III

Completed
A Randomized, Sham-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Intrathecal OAV101 in Type 2 Spinal Muscular Atrophy (SMA) Patients Who Are ≥ 2 to < 18 Years of Age, Treatment Naive, Sitting, and Never Ambulatory

  • Condition/Disease

    Patients aged 2 to under 18 years with treatment-naïve, late-onset type 2 spinal muscular atrophy (SMA) who are able to sit but have never walked.

  • Test Drug

    OAV101

Participate Sites
2Sites

Not yet recruiting1Sites

Study ended1Sites

2019-08-31 - 2024-06-03

Phase III

A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of a High Dose of Eteplirsen, Preceded by an Open-label Dose Escalation, in Patients with Duchenne Muscular Dystrophy With Deletion Mutations Amenable to Exon 51 Skipping

  • Condition/Disease

    Duchenne Muscular Dystrophy

  • Test Drug

    Eteplirsen

Participate Sites
2Sites

Recruiting2Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB